Skip to content
Menu

Praxis Precision Medicines, Inc. PRAX

Full chart Compare
Set alert

Price alert · PRAX

All alert types
304.41 USD -6.49 (-2.09%)

As ofNov 20, 2026, 2:50 PM EST

303.13 Day range 308.61
164.09 52-week range 386.33
YTD
+3.28%
1 year
+85.51%

5D -24.62 (-7.48%)

300310320330MonTueWedThuFri304.58
Market cap
8.52B
EPS (ttm)
-12.82
Shares out
27.95M
Forward P/E
-31.69
YTD return
+3.28%
1-year return
+85.51%
50-day average
287.32
200-day average
314.51
Enterprise value
7.79B
Price / book
6.90
Volume
504.41K
Avg volume
473.73K
Open
304.98
Previous close
310.90
Day's range
303.13 – 308.61
52-week range
164.09 – 386.33
Beta
2.84
Analysts
Strong Buy
Price target
674.43 (+121.6%)
Earnings date
Feb 18, 2027

Key statistics

Free cash flow
-214.15M
Total cash
745.32M
Total debt
732.00K
Return on equity
-44.84%
Short % of float
15.09%

Fundamental scorecard

4 of 25 checks passed on PRAX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PRAX Revenue — quarterly 0
PRAX Net income — quarterly -94.23M
PRAX EPS — quarterly -3.23

Earnings

PRAX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 18, 2027Dec 30, 2026-4.08———
Nov 9, 2026Sep 30, 2026-3.54-3.23+0.31+8.76%
Aug 6, 2026Jun 30, 2026-3.67-2.87+0.80+21.80%
May 7, 2026Mar 31, 2026-3.58-3.20+0.38+10.61%
Feb 19, 2026Dec 31, 2025-3.13-3.50-0.37-11.97%
Nov 5, 2025Sep 30, 2025-3.45-3.36+0.09+2.61%

Upgrades / downgrades

PRAX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 17, 2026Wells FargoupEqual-WeightOverweight
Nov 16, 2026GuggenheimmainBuyBuy
Nov 16, 2026BairdmainOutperformOutperform
Nov 10, 2026RBC CapitalmainOutperformOutperform
Nov 10, 2026WedbushmainUnderperformUnderperform
Nov 10, 2026Wells FargomainEqual-WeightEqual-Weight

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PRAX — it syncs with the Stock Master app.

Insider holders

PRAX insider holders
InsiderRelationLatest transactionDateShares held
ADAGE CAPITAL MANAGEMENT, L.P.Beneficial Owner of more than 10% of a Class of SecuritySaleOct 15, 20250
ARBUCKLE STUART ADirectorStock Award(Grant)Jun 9, 20262,537
KELLY TIMOTHY EDWINChief Financial OfficerStock Award(Grant)May 13, 202631,167
KINDLER JEFFREY BDirectorStock Award(Grant)Jun 9, 20262,537
MASTROCOLA LAURENOfficerStock Award(Grant)May 13, 202613,572
MITCHELL DEAN JDirectorStock Award(Grant)Jun 9, 202618,622

Institution ownership

PRAX institution ownership
Holder% heldSharesValueReported
Janus Henderson Group Ltd.12.34%3,449,9501.07BSep 29, 2026
FMR, LLC9.44%2,637,857820.11MSep 29, 2026
Blackrock Inc.7.99%2,232,814694.18MSep 29, 2026
Perceptive Advisors Llc7.24%2,024,781629.50MSep 29, 2026
Baker Bros. Advisors, LP6.27%1,753,198545.07MSep 29, 2026
Orbis Allan Gray Ltd4.87%1,360,049422.84MSep 29, 2026

Fund ownership

PRAX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%885,411275.27MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.33%650,750202.32MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%639,578198.84MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.53%427,949133.05MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.46%409,429127.29MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.45%405,016125.92MJun 29, 2026